Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

NCT01124708 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

ADHD

Interventions

DRUG: TC-5619-238
DRUG: Placebo

Sponsor

Targacept Inc.